annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 5A Prospective study of wide local excision and endocrine therapy without
radiotherapy (WORTH) for node-negative, estrogen receptor-positive early
breast cancer with negative histologic margins (WORTH trial, Protocol 1):
Five-year interim results. (Abstract #568)
R. Nishimura, S. Ohsumi, H. Inaji, Y. Ohashi, K. Suemasu, N. Masuda, S. Akashi-
Tanaka, S. Murakami, T. Ikeda, T. Nishi, Japanese Breast Conserving Treatment
Study Group
Brd. 5B Use of an RNA interference screen-derived mitotic and ceramide pathway
metagene to predict response to paclitaxel combination chemotherapy in
primary breast cancer. (Abstract #569)
C. Swanton, N. Juul, J. M. Larkin, A. Eklund, Q. Li, C. Desmedt, C. Sotiriou,
L. Pusztai, Z. Szallasi
Brd. 5C Cosmetic outcome two and three years after intraoperative radiotherapy
compared with external beam radiotherapy for early breast cancer: An
objective assessment of patients from a randomized controlled trial.
(Abstract #570)
M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, D. J. Joseph, on behalf of
the TARGIT Trialists’ Group
Brd. 5D Cardiovascular safety of adjuvant bevacizumab for breast cancer. (Abstract
#571)
E. L. Mayer, A. Nohria, K. Miller, H. S. Rugo, L. A. Carey, N. Ryabin, R. S. Gelman,
E. P. Winer, H. J. Burstein
Brd. 5E Association of gene copy number alterations in formalin-fixed, paraffinembedded
tumors with prognostic molecular and pathologic tumor subtypes
in early-stage breast cancer. (Abstract #572)
J. L. Murray, P. Thompson, M. Tuna, A. M. Brewster, K. Do, M. E. Edgerton,
A. Sahin, G. B. Mills, S. Tsachavidis, M. Bondy
Brd. 5F Primary endocrine therapy for early operable primary breast cancer in elderly
women: Survival analysis of a large series from a single institution. (Abstract
#573)
W. Al-Khyatt, B. M. Syed, D. A. Morgan, A. R. Green, I. O. Ellis, K. Cheung
Brd. 5G Do socioeconomic factors and insurance explain racial/ethnic disparities in
receipt of recommended breast cancer care? (Abstract #574)
R. A. Freedman, K. S. Virgo, Y. He, A. Pavluck, E. P. Winer, E. M. Ward,
N. L. Keating
Brd. 5H Chemotherapy (CT) versus tamoxifen (T) versus chemoterapy plus tamoxifen
(CTT) in patients with node-positive (N�), estrogen receptor-positive (ER�)
breast cancer (bca): Very late results of an Italian multicentric trial. (Abstract
#575)
F. Boccardo, P. Guglielmini, A. Marasco, A. Rubagotti
Brd. 6A Randomized phase II trial of preoperative lapatinib versus placebo in HER2positive
breast cancer. (Abstract #576)
A. De Censi, M. Puntoni, G. Pruneri, A. Guerrieri-Gonzaga, M. Cazzaniga,
H. A. Johansson, O. Pala, G. Pagani, M. Marrè Brunenghi, B. Bonanni
Brd. 6B Decision analysis: Excision alone versus excision plus radiation therapy for
ductal carcinoma in situ. (Abstract #577)
R. S. Punglia, J. S. Wong, H. J. Burstein, J. C. Weeks
Brd. 6C Effect of early discontinuation and nonadherence to adjuvant hormone
therapy on mortality in women with breast cancer. (Abstract #578)
D. L. Hershman, T. H. Shao, L. Kushi, D. Buono, W. Tsai, L. Fehrenbacher,
A. I. Neugut
Brd. 6D Circulating tumor cells (CTC) and circulating endothelial cells (CEC) in
patients (pts) receiving adjuvant bevacizumab (B) plus dose-dense (dd)
doxorubicin/cyclophosphamide (AC) followed by nab-paclitaxel (nab-P) for
early-stage breast cancer (ESBC). (Abstract #579)
M. E. Melisko, S. Greenberg, M. N. Dickler, M. M. Moasser, J. H. Scott,
A. N. DeLuca, D. H. Moore, C. Hudis, J. W. Park, H. S. Rugo
149
SATURDAY